Nxera Pharma Co., Ltd.

Nxera reported first-half revenue of JPY 18.9 billion, up 25% from JPY 15.1 billion a year ago. Operating profit improved from a JPY 2.8 billion loss to a JPY 1.9 billion profit, and core operating profit rose from JPY 364 million to JPY 6.5 billion. Product sales increased from JPY 7.5 billion to JPY 9.9 billion, while milestone revenue grew from JPY 5.0 billion to JPY 8.0 billion. PIVLAZ first-half sales were JPY 6.3 billion, up 9%, and QUVIVIQ sales were JPY 3.6 billion, up 127%. Management said both the commercial products business and the platform business were profitable on a core basis, and SG&A and R&D were tracking at 49% and 50% of full-year forecast, respectively. For the year, the company reiterated net product sales target of more than JPY 19.5 billion and said it is on track to achieve full-year IFRS profitability; it also said PIVLAZ and QUVIVIQ remain in line with expectations, with QUVIVIQ full-year revenue projected at JPY 5 billion to JPY 6 billion. Chris also reiterated a 2030 target of JPY 40 billion to JPY 50 billion in product revenue and an operating margin above 30%, and noted the broader 2030 vision would imply roughly JPY 50 billion to JPY 60 billion total when adding platform and milestone income.

Chris Cargill framed the quarter as evidence that Nxera is moving “from investment to delivery,” emphasizing revenue growth, profitability, and external validation of the science. He repeatedly highlighted the company’s four “value engines” — products, platforms, pipeline, and partnerships — and said each is now substantial and independently valuable. He also stressed that Nxera is focused on differentiated chemistry against clinically or biologically validated GPCR targets, not on broad first-in-class risk. His tone was upbeat and confident, especially around the Centessa/Lilly transaction, the AI platform, and the company’s ability to secure major new deals.

Hironoshin Nomura focused on the financial bridge from milestone-heavy revenue to a more balanced and profitable model. He noted that revenue growth to JPY 18.9 billion was driven mainly by milestone revenue of JPY 8.0 billion and product sales of JPY 9.9 billion, and said the company’s spend is on track with SG&A and R&D at 49% and 50% of full-year forecast. He also emphasized that the platform business is harder to control because it depends on partner milestones, so the company wants to stabilize revenue through the commercial business. In Q&A, he said PIVLAZ and QUVIVIQ are both “in line” with plan, while warning that QUVIVIQ revenue can move with Shionogi inventory levels and is not directly synchronized with end demand.

Analysts pressed on the pace and likelihood of completing out-licensing deals for the company’s two key clinical assets. Management said discussions are ongoing, expects at least one new major out-license this year, and confirmed that if no licensing deal is signed, Nxera does not intend to run global phase II studies itself; instead, it would prefer a major pharma partner or possibly a spinco funded by venture capital. Questions also focused on QUVIVIQ growth and whether the full-year target could be raised, but management said the product remains in line with plan and that inventory timing at partner Shionogi can distort quarterly revenue. Another topic was valuation and listing strategy: Chris said Nxera is not considering delisting from Japan, but the board is already considering a carve-out listing and he believes U.S. investors would value the pipeline and AI platform more highly. He also clarified that Lilly’s acquisition of Centessa does not change the confidentiality of Nxera’s deal, but milestones remain due and the referenced royalties are single-digit.